High Dose Inhaled Fluticasone Propionate Improves FEV1 and Results in Reduction of Oral Glucocorticoid Dose in Glucocorticoid-Dependent Children with Severe Asthma
Abstract:A retrospective chart review was performed on eight pediatric patients with glucocorticoid (GC)-dependent asthma who had been switched to fluticasone propionate (FP). A significant increase was noted in average forced expiratory volume in 1 second (FEV1) and forced expiratory flow 25-75% (FEF25-75) at 6 and 12 months. Significant reductions were noted in the oral GC dose at 6 and 12 months with a reduction at 12 months of almost 16.5 mg/day or 65% of the initial oral GC dose. This study suggests that high-dose FP use in children with oral GC-dependent asthma has oral GC sparing effects while improving FEV1 and FEF25-75.
Document Type: Regular Paper
Publication date: November 1, 2001
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- ingentaconnect is not responsible for the content or availability of external websites